肺癌市场按类型、药物类别、分子类型、给药途径、疾病分期、年龄层、性别、分销管道、最终用户和地区划分

预计 2025 年肺癌市场价值将达到 281.2 亿美元，到 2032 年预计将达到 645.3 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 12.6%。

全球肺癌市场是癌症治疗领域最重要的细分市场之一，其驱动力来自肺癌这一持续存在的全球性挑战，而肺癌是癌症相关死亡的主要原因。这种恶性肿瘤每年影响数百万患者，其中非小细胞肺癌 (NSCLC) 约占所有病例的 85%，小细胞肺癌 (SCLC) 占其余 15%。该市场治疗性介入，包括化疗、标靶治疗、免疫治疗、放射线治疗和手术，以及诊断工具和支持性治疗。

吸烟习惯、环境污染物、职业危害和遗传易感性导致的癌症盛行率不断上升，持续刺激全球癌症需求。精准医疗方法的引入，例如生物标记主导疗法、免疫查核点抑制剂和蛋白酪氨酸激酶抑制剂，见证了癌症治疗领域的突破，并显着改善了患者的预后。医疗基础设施的改善、人们对早期检测项目的认识不断提高，以及製药公司对研发活动的大力投入，共同塑造市场的发展轨迹。

市场动态

全球肺癌市场受到多种驱动因素​​的推动，这些因素共同促成了其强劲的成长轨迹，但同时，它也面临着某些阻碍因素，这些因素在减缓扩张速度的同时，也为未来的市场发展提供了重大机会。关键的市场驱动因素包括由于烟草消费量增加、空气污染、职业性致癌物质暴露和遗传易感性导致的全球肺癌发病率上升，这些因素共同扩大了需要治疗性介入的患者群体。

免疫疗法的突破性进展，尤其是PD-1/PD-L1抑制剂等免疫查核点抑制剂，改变了治疗模式，并创造了巨大的市场机会。同时，针对EGFR、ALK和ROS1等特定基因突变的标靶治疗的开发，使得个体化治疗方案得以实现，并获得了卓越的疗效。新兴国家医疗基础设施的改善、医疗支出的增加以及透过筛检计画提高早期诊断意识，进一步推动了市场的成长。

然而，市场扩张面临着巨大的限制因素，包括创新癌症治疗的成本非常高，限制了药物的获取，尤其是在新兴市场；严格的法律规范延长了药物核准时间；以及药物开发过程的复杂性，需要大量投资但结果不确定。

专利到期将导致现有药物面临定价压力并损失市场份额。然而，透过开发联合治疗来提高疗效、拓展尚未开发的地理市场、推动伴随诊断技术进步以实现个人化医疗，以及整合人工智慧和机器学习技术以改善诊断和治疗方案，这些都蕴藏着巨大的商机。对早期癌症治疗的日益关注、新型药物输送系统的开发以及製药公司与研究机构之间合作的加强，都为市场扩张和技术创新开闢了新的途径。

本次调查的主要特点

• 本报告对全球肺癌市场进行了详细分析，提供了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），以 2024 年为基准年。
• 它还强调了各个领域的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、财务业绩和策略等参数概述了全球肺癌市场的主要企业。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球肺癌市场报告涉及该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 透过用于分析全球肺癌市场的各种策略矩阵，相关人员将更容易做出决策。

目录

第 1 章：调查目标与先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章：市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 产业趋势

4. 2020-2032 年全球肺癌市场（按类型）

• 非小细胞肺癌（NSCLC）
• 小细胞肺癌（SCLC）
• 肺类癌

5. 2020-2032 年全球肺癌市场（依药物类别）

• 细胞毒性化疗
• 标靶治疗
• 免疫疗法
• 其他的

6. 2020-2032 年全球肺癌市场（以分子型态）

• 低分子
• 生物製药

7. 2025-2032 年全球肺癌市场（依治疗途径）

• 肠外
• 口服

8. 2020-2032 年全球肺癌市场分阶段

• 早期癌症（I-II期）
• 局部晚期癌症（III期）
• 转移性/进行性（IV期）

9. 2020-2032 年全球肺癌市场（依年龄层划分）

• 成人
• 孩子们
• 老年人

第 10 章。 2020-2032 年全球肺癌市场（依性别）

• 男性
• 女士

第 11 章：2020-2032 年全球肺癌市场（按通路）

• 医院药房
• 零售药局
• 网路药局

第 12 章：2020 年至 2032 年全球肺癌市场（按最终用户划分）

• 医院
• 诊断实验室
• 癌症专科诊所
• 居家医疗
• 其他（研究和学术机构等）

第 13 章：2020-2032 年全球肺癌市场（按地区）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第十四章竞争格局

• Hoffmann-La Roche Ltd.
• Novartis AG
• AstraZeneca plc
• Bristol Myers Squibb Company
• Merck and Co., Inc.（MSD）
• Pfizer Inc.
• Eli Lilly and Company
• Johnson and Johnson（Janssen Biotech, Inc.）
• Amgen Inc.
• AbbVie Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Company, Limited
• Astellas Pharma Inc.
• Regeneron Pharmaceuticals, Inc.

第 15 章分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第十六章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Lung Cancer Market is estimated to be valued at USD 28.12 Bn in 2025 and is expected to reach USD 64.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2032.

The global lung cancer market represents one of the most critical segments within the oncology therapeutics landscape, driven by the persistent challenge of lung cancer as the leading cause of cancer-related mortality worldwide. This malignancy affects millions of patients annually, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases, while small cell lung cancer (SCLC) comprises the remaining 15%. The market encompasses a comprehensive spectrum of therapeutic interventions including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, alongside diagnostic tools and supportive care solutions.

Rising prevalence rates attributed to smoking habits, environmental pollutants, occupational hazards, and genetic predispositions continue to fuel demand globally. The therapeutic landscape has witnessed revolutionary advancements through the introduction of precision medicine approaches, including biomarker-driven treatments, immune checkpoint inhibitors, and tyrosine kinase inhibitors that have significantly improved patient outcomes. Healthcare infrastructure development, increasing awareness about early detection programs, and substantial investments in research and development activities by pharmaceutical companies are collectively shaping the market trajectory.

Market Dynamics

The global lung cancer market is propelled by multiple driving factors that collectively contribute to its robust growth trajectory, while simultaneously facing certain constraints that moderate expansion rates, yet presenting significant opportunities for future development. Primary market drivers include the escalating global incidence of lung cancer due to increasing tobacco consumption, air pollution, occupational exposure to carcinogens, and genetic susceptibilities, which collectively expand the patient population requiring therapeutic interventions.

The revolutionary advancement in immunotherapy treatments, particularly immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors, has transformed treatment paradigms and created substantial market opportunities, while targeted therapy developments focusing on specific genetic mutations like EGFR, ALK, and ROS1 have enabled personalized treatment approaches that demonstrate superior efficacy rates. Healthcare infrastructure improvements in emerging economies, coupled with increasing healthcare expenditure and growing awareness about early diagnosis through screening programs, further accelerate the market growth.

However, market expansion faces significant restraints including the extremely high costs associated with innovative cancer treatments, which limit accessibility particularly in developing regions, stringent regulatory frameworks that prolong drug approval timelines, and the complex nature of drug development processes that require substantial investments with uncertain outcomes.

Patent expiration of blockbuster drugs creates pricing pressures and market share erosion for established players. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance treatment efficacy, expansion into untapped geographical markets, advancement in companion diagnostics for personalized medicine, and the integration of artificial intelligence and machine learning technologies for improved diagnosis and treatment selection. The growing focus on early-stage cancer treatment, development of novel drug delivery systems, and increasing collaborations between pharmaceutical companies and research institutions present additional avenues for market expansion and innovation.

Key Features of the Study

• This report provides in-depth analysis of the global lung cancer market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca plc, Bristol Myers Squibb Company, Merck and Co., Inc. (MSD), Pfizer Inc., Eli Lilly and Company, Johnson and Johnson (Janssen Biotech, Inc.), Amgen Inc., AbbVie Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Astellas Pharma Inc., and Regeneron Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer market.

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Small Cell Lung Cancer (SCLC)
  • Lung Carcinoid Tumor
• Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Cytotoxic Chemotherapy
  • Alkylating agents (cisplatin, carboplatin, etc.)
  • Antimetabolites (pemetrexed, gemcitabine)
  • Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
  • Topoisomerase inhibitors (etoposide, irinotecan)
  • Others
  • Targeted Therapy
  • EGFR Inhibitors (Erlotinib, etc.)
  • ALK Inhibitors (Crizotinib, etc.)
  • ROS1 Inhibitors (Entrectinib, etc.)
  • BRAF/MEK Inhibitors (Dabrafenib, etc.)
  • MET Inhibitors (Capmatinib, etc.)
  • RET Inhibitors (Selpercatinib, etc.)
  • HER2 Inhibitors (Trastuzumab, etc.)
  • Immunotherapy
  • PD-1 Inhibitors (Nivolumab, etc.)
  • PD-L1 Inhibitors (Atezolizumab, etc.)
  • CTLA-4 Inhibitors (Ipilimumab, etc.)
  • Other Combination Therapeutics
• Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Small Molecules
  • Biologics
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Parenteral
  • Oral
• Stage of Disease Insights (Revenue, USD Bn, 2020 - 2032)
  • Early-stage (Stage I-II)
  • Locally Advanced (Stage III)
  • Metastatic/Advanced (Stage IV)
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Pediatric
  • Geriatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Diagnostic Laboratories
  • Specialty Cancer Clinics
  • Homecare Settings
  • Others (Research and Academic Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • AstraZeneca plc
  • Bristol Myers Squibb Company
  • Merck and Co., Inc. (MSD)
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson and Johnson (Janssen Biotech, Inc.)
  • Amgen Inc.
  • AbbVie Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • Astellas Pharma Inc.
  • Regeneron Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Lung Cancer Market, By Type
  • Global Lung Cancer Market, By Drug Class
  • Global Lung Cancer Market, By Molecule Type
  • Global Lung Cancer Market, By Route of Administration
  • Global Lung Cancer Market, By Stage of Disease
  • Global Lung Cancer Market, By Age Group
  • Global Lung Cancer Market, By Gender
  • Global Lung Cancer Market, By Distribution Channel
  • Global Lung Cancer Market, By End User
  • Global Lung Cancer Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Lung Cancer Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Non-Small Cell Lung Cancer (NSCLC)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Adenocarcinoma
    • Squamous Cell Carcinoma
    • Large Cell Carcinoma
• Small Cell Lung Cancer (SCLC)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Carcinoid Tumor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Lung Cancer Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Cytotoxic Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Alkylating agents (cisplatin, carboplatin, etc.)
    • Antimetabolites (pemetrexed, gemcitabine)
    • Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
    • Topoisomerase inhibitors (etoposide, irinotecan)
    • Others
• Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • EGFR Inhibitors (Erlotinib, etc.)
    • ALK Inhibitors (Crizotinib, etc.)
    • ROS1 Inhibitors (Entrectinib, etc.)
    • BRAF/MEK Inhibitors (Dabrafenib, etc.)
    • MET Inhibitors (Capmatinib, etc.)
    • RET Inhibitors (Selpercatinib, etc.)
    • HER2 Inhibitors (Trastuzumab, etc.)
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • PD-1 Inhibitors (Nivolumab, etc.)
    • PD-L1 Inhibitors (Atezolizumab, etc.)
    • CTLA-4 Inhibitors (Ipilimumab, etc.)
• Other Combination Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Lung Cancer Market, By Molecule Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Small Molecules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Lung Cancer Market, By Route of Administration, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Lung Cancer Market, By Stage of Disease, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Early-stage (Stage I-II)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Locally Advanced (Stage III)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Metastatic/Advanced (Stage IV)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Lung Cancer Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Lung Cancer Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Lung Cancer Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Lung Cancer Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Cancer Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Homecare Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Research and Academic Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Lung Cancer Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

14. Competitive Landscape

• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck and Co., Inc. (MSD)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson and Johnson (Janssen Biotech, Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo Company, Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

15. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

16. References and Research Methodology

• References
• Research Methodology
• About us